Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6-desoxy-6-methylenenaltrexone
2. Nalmefene
3. Revex
4. Selincro
1. 58895-64-0
2. Nalmefene Hcl
3. Revex
4. Nalmefenehydrochloride
5. Jf-1 Hydrochloride
6. K7k69qc05x
7. (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydrochloride
8. Unii-k7k69qc05x
9. Revex (tn)
10. 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, , Hydrochloride
11. Schembl628721
12. Chembl1201152
13. Dtxsid70891705
14. Bcp08346
15. Nalmefene Hydrochloride [mi]
16. Mfcd27937056
17. Akos016340557
18. Ccg-221179
19. Hs-0037
20. Nalmefene Hydrochloride [mart.]
21. Nalmefene Hydrochloride [vandf]
22. Nalmefene Hydrochloride [who-dd]
23. Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, Hydrochloride, (5alpha)-
24. B7584
25. Nalmefene Hydrochloride [orange Book]
26. D02104
27. Sr-01000000007
28. Sr-01000000007-2
29. Q27282058
30. 17-cyclopropylmethyl-4,5a-epoxy-6-methylenemorphinan-3,14-diol
31. (5?)-17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol Hydrochloride
32. 17-cyclopropylmethyl-4,5a-epoxy-6-methylenemorphinan-3,14-diol Hydrochloride
33. (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol,hydrochloride
Molecular Weight | 375.9 g/mol |
---|---|
Molecular Formula | C21H26ClNO3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Exact Mass | 375.1601214 g/mol |
Monoisotopic Mass | 375.1601214 g/mol |
Topological Polar Surface Area | 52.9 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 618 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5484
Submission : 1984-08-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34367
Submission : 2019-12-13
Status : Active
Type : II
Date of Issue : 2025-02-11
Valid Till : 2027-06-09
Written Confirmation Number : WC-0278
Address of the Firm :
NDC Package Code : 73548-8019
Start Marketing Date : 2024-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-06-23
Pay. Date : 2022-04-01
DMF Number : 36751
Submission : 2022-03-21
Status : Active
Type : II
NDC Package Code : 82712-1002
Start Marketing Date : 2022-05-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (350g/350g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-08-25
Pay. Date : 2019-08-22
DMF Number : 15663
Submission : 2001-10-10
Status : Active
Type : II
NDC Package Code : 0406-1340
Start Marketing Date : 2025-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35829
Submission : 2021-11-10
Status : Active
Type : II
NDC Package Code : 0406-5690
Start Marketing Date : 2019-03-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5642
Submission : 1984-12-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8507
Submission : 1990-03-30
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
19
PharmaCompass offers a list of Nalmefene Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nalmefene Hydrochloride manufacturer or Nalmefene Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nalmefene Hydrochloride manufacturer or Nalmefene Hydrochloride supplier.
PharmaCompass also assists you with knowing the Nalmefene Hydrochloride API Price utilized in the formulation of products. Nalmefene Hydrochloride API Price is not always fixed or binding as the Nalmefene Hydrochloride Price is obtained through a variety of data sources. The Nalmefene Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nalmefene HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nalmefene HCl, including repackagers and relabelers. The FDA regulates Nalmefene HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nalmefene HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nalmefene HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nalmefene HCl supplier is an individual or a company that provides Nalmefene HCl active pharmaceutical ingredient (API) or Nalmefene HCl finished formulations upon request. The Nalmefene HCl suppliers may include Nalmefene HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Nalmefene HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nalmefene HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Nalmefene HCl active pharmaceutical ingredient (API) in detail. Different forms of Nalmefene HCl DMFs exist exist since differing nations have different regulations, such as Nalmefene HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nalmefene HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Nalmefene HCl USDMF includes data on Nalmefene HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nalmefene HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nalmefene HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nalmefene HCl Drug Master File in Japan (Nalmefene HCl JDMF) empowers Nalmefene HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nalmefene HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Nalmefene HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nalmefene HCl suppliers with JDMF on PharmaCompass.
A Nalmefene HCl written confirmation (Nalmefene HCl WC) is an official document issued by a regulatory agency to a Nalmefene HCl manufacturer, verifying that the manufacturing facility of a Nalmefene HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nalmefene HCl APIs or Nalmefene HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Nalmefene HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Nalmefene HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nalmefene HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nalmefene HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nalmefene HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nalmefene HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nalmefene HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nalmefene HCl suppliers with NDC on PharmaCompass.
Nalmefene HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nalmefene HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nalmefene HCl GMP manufacturer or Nalmefene HCl GMP API supplier for your needs.
A Nalmefene HCl CoA (Certificate of Analysis) is a formal document that attests to Nalmefene HCl's compliance with Nalmefene HCl specifications and serves as a tool for batch-level quality control.
Nalmefene HCl CoA mostly includes findings from lab analyses of a specific batch. For each Nalmefene HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nalmefene HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Nalmefene HCl EP), Nalmefene HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nalmefene HCl USP).